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Abstract
Hepatocellular carcinoma (HCC) is one of the most lethal and chemo-refractory cancers, clearly, 
alternative treatment strategies are needed. We utilized 10nm gold nanoparticles as a scaffold to 
synthesize nanoconjugates bearing a targeting antibody (cetuximab, C225) and gemcitabine. 
Loading efficiency of gemcitabine on the gold nanoconjugates was 30%. Targeted gold 
nanoconjugates in combination with RF were selectively cytotoxic to EGFR expressing Hep3B 
and SNU449 cells when compared to isotype particles with/without RF (p<0.05). In animal 
experiments, targeted gold nanoconjugates halted the growth of subcutaneous Hep3B xenografts 
in combination with RF exposure (p<0.05). These xenografts also demonstrated increased 
apoptosis, necrosis and decreased proliferation compared to controls. Normal tissues were 
unharmed. We have demonstrated that non-invasive RF-induced hyperthermia when combined 
with targeted delivery of gemcitabine is more effective and safe at dosages ~275-fold lower than 
the current clinically-delivered systemic dose of gemcitabine.
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INTRODUCTION
Cancer cell targeted drug delivery that minimizes toxicity and maximizes therapeutic benefit 
remains a fundamental challenge for successful cancer therapy. Over the past decade 
emerging nanotechnologies have shown promise in conquering barriers to transport of 
chemotherapeutic and biologic agents to malignant tissue while sparing normal organs. 
Nanoparticle-based combination therapies are of particular interest. However, translation of 
these systems to the clinic has been slow. The aim of the present study is to devise a EGFR-
targeted non-invasive chemo-thermo-therapy that can be readily translated to the clinic by 
taking advantage of recent advances in our understanding of a) targeted drug delivery and b) 
thermal therapy of cancers. The premise of such work is based on the synergistic interaction 
of conventional cytotoxic chemotherapeutic agents and hyperthermia (1). We chose to direct 
our efforts at hepatocellular carcinoma (HCC) because conventional strategies have failed to 
provide relevant survival benefit and are too toxic in the majority of patients who also have 
concomitant underlying hepatic dysfunction (2). Challenges in advanced HCC treatment, 
therefore, exemplify the currently unmet need for novel, less toxic, and more effective 
strategies.
A growing body of experimental and theoretical work has demonstrated that metallic or 
semiconducting nanoparticles heat in an electromagnetic field, i.e. a near-infrared (NIR) or 
radiofrequency (RF) field (3–8). While NIR penetration in human tissues is limited to a few 
centimeters, shortwave RF fields in the megahertz range offer the benefit of full-body 
penetration. Prior in vitro and in vivo studies have demonstrated that this RF field-based 
nanohyperthermia system is safe and effective in a rabbit model of liver cancer after direct 
intra-tumoral injection of single-walled carbon nanotubes, and demonstrated efficacy 
without toxicity after systemic delivery of EGFR-targeted gold nanoparticles (AuNPs) in a 
mouse model of pancreatic adenocarcinoma (5, 6). In regards to cancer specific-targeted 
drug delivery, the list of conventional chemotherapeutic drugs that have been delivered 
using nanoparticles continues to grow and are reviewed elsewhere (9–11). Of these 
nanovectors, AuNPs are most extensively studied because they are already in clinical use 
and their physiochemical properties allow for a multitude of possible chemical linkages to 
targeting agents. For instance, Patra et al. successfully delivered gemcitabine non-covalently 
conjugated to AuNPs along with a targeting antibody (cetuximab, C225) against epidermal 
growth factor receptor (EGFR) in pancreatic adenocarcinoma cells (12).
Given these findings, we hypothesized that carefully-designed nanoparticles bearing a 
targeting antibody and a chemotherapeutic agent could be systemically delivered to human 
HCC xenografts. Upon delivery these conjugates would undergo pH-responsive release of 
the drug. Subsequent non-invasive RF induced-hyperthermia would then enhance tumor cell 
death because of the presence of drug and/or nanoparticles.
MATERIALS AND METHODS
Cell lines and Reagents
All cell lines (Hep3B, HepG2, SNU182, SNU475, SNU398 and SNU 449) were purchased 
from the American type culture collection (ATCC) and maintained as per the instructions of 
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the supplier. The short tandem repeat fingerprint was confirmed by the Cell Line 
Characterization Core Service (M. D. Anderson Cancer Center, Houston, TX) within one 
year of the experiments. Standard cell culture coated 12- and 24-well plates were used for 
experiments (Corning Inc., Corning, NY). Cetuximab (C225, Bristol-Myers Squibb, New 
York, NY), a chimeric monoclonal IgG1 antibody against human EGFR-1, gemcitabine (Eli 
Lilly, Indianapolis, IN), the heterobifunctional alkane monothiol linker SPT-0012 
(Sensopath Technologies, Inc., Bozeman, MT), mPEG-SH (Nanocs, New York, NY), and 
10nm spherical AuNPs (Ted Pella, Inc., Redding, CA) were used in synthesizing the gold 
nanoconjugates. For immunohistochemistry, mouse anti-human Ki67 (M7240, Dako, 
Carpinteria, CA), rabbit anti-cleaved caspase 3 (Asp175, Cell Signaling, Danvers, MA) and 
rat anti-BrdU (Abcam, Cambridge, MA) were used. Rat and mouse primary antibodies were 
detected using a HRP/Polymer kit from Biocare, while rabbit antibodies were detected using 
Envision+/HRP from Dako (Carpinteria, CA)
Synthesis and characterization of gold conjugates
Gold nanoconjugates were synthesized as described in detail previously with some 
modifications that are discussed here (6, 13). The stock buffer from as purchased citrate-
capped AuNPs was exchanged with a borate buffer (Sigma-Aldrich, St. Lous, MO) using 
50kDa centrifugation filter (50 kDa, Amicon, Milipore, Billerica, MA). Gemcitabine was 
added to 50 μg/ml aliquots of AuNPs in borate buffer to a final gemcitabine concentration of 
0 to 100 μg/ml and incubated for a variable duration. Incubation of 50 μg /ml AuNP with 10 
μg/ml gemcitabine for 1 hour was optimal and was used for subsequent conjugations. 
Cetuximab (C225) was separately modified using a heterobifunctional alkane linker as 
described elsewhere (6, 13). This modified antibody was then added to AuNP-gemcitabine 
conjugates (30 μg of C225-linker to 50 μg Au in each ml of reaction mixture, to obtain 
AuNP-C225-gemcitabine (ACG) nanoparticles (2–3 h incubation at room temperature). The 
conjugates were further modified using methoxypoly(ethylene glycol)-thiol (mPEG-SH) at a 
final concentration of 100uM in the reaction mixture for 1 hour to yield AuNP-C225-
gemcitabine-mPEG (ACGP) nanoparticles. Successful conjugation and stability after 150 
mM NaCl challenge was analyzed at each step using UV-Vis spectroscopy (Applied 
Nanofluorescence, Houston, TX) and dynamic light scattering (Malvern Instruments, 
Westborough, MA). Finally, the gold nanoconjugates were purified using filter 
centrifugation (50 kDa, Amicon, Milipore, Billerica, MA) to remove excess unconjugated 
gemcitabine and mPEG-SH. Isotype control AuNP-IgG-gemcitabine-mPEG (AIGP) 
nanoparticles were synthesized similarly by using isotype control human IgG in place of 
C225. Gemcitabine loading was determined by measuring unbound gemcitabine that was 
removed after filter centrifugation using reverse phase high performance liquid 
chromatography (HPLC) described elsewhere (14). Briefly, the UV absorbance of 
chromatographic peaks was recorded (Waters 1525 HPLC system, Milford, MA) at 275nm 
after separation through a Phenomenex Luna 5uC18(2) 100A column (250 x 4.6 mm, 
particle size 5 microns silica) using 0.1% TFA-water/acetonitrile at ambient temperature. A 
standard curve of area-under-the-curve corresponding to a gemcitabine elution fraction was 
generated using known concentrations and unknown concentrations were determined.
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In order to understand the release kinetics of gemcitabine from these conjugates, ACGP 
nanoparticles were centrifuged at 13,200 RPM for 30 minutes to remove unbound C225, 
gemcitabine, and mPEG. The pellet was resuspended in a physiologic buffer (PBS+1g/dL 
bovine serum albumin) and aliquoted into several tubes. At each time point over the course 
of 24 hours, the colloidal suspension in the physiologic media was centrifuged at 13200 
RPM for 1 hour to pellet all the ACGP conjugates; the supernatant was removed and 
analyzed by HPLC. The gemcitabine concentration was determined by comparing to a 
known standard. These experiments were repeated at pH 5, pH 6 and with or without non-
invasive RF field exposure (600 W, 13.56 MHz, one minute duration). To assess the 
conjugation of C225-L to AuNPs, we labeled C225-L with AlexaFluor-647 fluorophore, as 
previously described (15). Briefly, after incubating AuNPs with a known concentration of 
C225-L, the conjugates were pelleted. Fluorescence was measured in the supernatant and 
C225-L concentration quantified against a standard scale. We estimated 600ng of C225-L on 
each microgram of AuNP.
In vitro studies
Flow cytometry was performed using a BD LSR II FACS unit (BD Biosciences, San Jose, 
CA). After trypsinization, approximately 1 million cells were incubated on ice with 
phycoerytherin (PE)- conjugated EGFR antibody or isotype control (BD Biosciences, San 
Jose, CA) for 30 minutes. Subsequently, the cells were resuspended in PBS and washed 
twice before analyzing with the FACS analysis (Excitation: 561nm, Emission: 570–597nm).
For inductively coupled plasma atomic mass spectrometry (ICP-MS), approximately 1 
million cells in adherent sub-confluent monolayers were incubated with targeted or isotype 
gold nanoconjugates (at Au concentration of 0.2 mg/ml) for 4 hours. The samples were 
washed twice with PBS and trypsinized. Cell pellets were digested with aqua regia (1 part 
nitric acid and 3 parts hydrochloric acid by volume). The gold concentration was determined 
using a Perkin Elmer Elan 9000 (Waltham, MA) ICP-MS instrument, as per manufacturer’s 
instructions.
Transmission electron microscopy (TEM) studies were performed as described previously 
(15). For cytotoxicity studies, exponentially-growing adherent monolayers were exposed to 
the varying conditions as mentioned in the text with or without RF exposure in a 12-well 
plate. Nanoparticles were administered by gold concentration at 0.2 mg/ml. The Kanzius RF 
generator set-up for in vitro studies has been described previously (15). Briefly, cells were 
plated in three adjacent wells of a 12-well plate. The plates were positioned on a Teflon 
holder in the RF field such that there was a uniform RF field across the three wells. The bulk 
media temperature remained <37°C for the exposure duration of 4.5 minutes. This value was 
determined to be LD75 of RF exposure for both cell lines under the stated conditions. 
Viability was measured using a standard MTT assay as a percentage of untreated controls.
In vivo studies
All mice were kept in accordance with an Institutional Animal Care and Use Committee 
approved protocol. A mouse model of liver cancer was generated using subcutaneous 
implantation of approximately 3 million cells in the dorsal midline of 4wk old BalbC/ Nu 
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mice. The cells were injected in a 200 μl final volume, mixed with matrigel (1:1 v:v), and 
mice were randomized to one of 5 groups as stated in the text (7 mice per group). After three 
weeks, the mice that did not form tumors were excluded. At this point the greatest tumor 
dimension (either height, width or length) of each group was ~0.5 cm. Animals were 
injected with or without gold nanoconjugates (AuNP concentration 10 mg/kg) systemically 
(intraperitoneal, IP) approximately 24 hours prior to RF exposure. This treatment was 
repeated twice a week and was continued over three weeks with mice receiving a total of six 
doses. For RF treatment, the mice were placed on the Rx head of the in vivo RF generator 
under anesthesia and grounded using a copper tape, as described previously (6). The 
temperature of the ectopic tumor was monitored continuously using an infrared (IR) thermal 
camera (FLIR SC 6000, FLIR Systems, Inc., Boston, MA). RF exposures were paused when 
the surface tumor temperature reached 43°C and were then resumed at 40°C for a total “RF 
on” duration of 10 minutes. A stock AuNP solution was used as an internal control to ensure 
calibration between RF exposures. Tumor volumes were calculated using the formula for an 
ellipsoid (π x length x width x height /6). Animals were sacrificed 24 hours after the last RF 
treatment or 48 hours after the last dose of nanoparticles. Tumors were harvested from all 
the mice and weighed. We administered 10 mg/kg BrdU (i.p.) 24 hours before sacrificing 
the animals. Tumors and other organs were harvested for mass determination, histological 
analysis, or ICP-MS. Specimens for ICP-MS were washed with PBS, wiped dry, weighed 
and then subjected to slow acid digestion as described above for in vitro studies. The gold 
concentration of each sample was determined by ICP according to the manufacturer’s 
recommendations (iCAP 6500, Thermo Fisher Scientific, Waltham, MA). For Au plasma 
level determination, blood was collected from the mandibular vein of live animals and intra-
cardiac puncture for terminal animals under isoflurane anesthesia.
For histological analysis, samples were formalin fixed and paraffin embedded. Five-micron 
sections were placed on unstained slides. Subsequent processing (H&E staining and 
immunohistochemistry, IHC) was performed on a Dako automated stainer as a single batch 
per antigen. For IHC, primary antibodies were detected using a colorimetric DAB stain. 
Three random high power fields (10 x objectives) were analyzed from a single section 
across the middle of each tumor. At least 3 tumors were analyzed per group on a 
multispectral scope (Olympus IX51 featuring a CRi Nuance camera, Hopkinton, MA). 
Staining was quantified using inForm™ (CRI, Capillary Life Sciences, Hopkinton, MA); 
pattern recognition software that subjects multispectral data to machine-learning algorithms 
for accurate quantification of staining.
Statistical Methods
Results are reported as mean±SEM unless otherwise noted. For all inferential statistics, null 
hypothesis was rejected at p<0.05. Two-sided student’s t-test was used for two-group means. 
Multiple group comparisons were performed using one-way ANOVA. All data was plotted 
and analyzed in Prism 5.0 La Jolla, CA
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RESULTS
Characterization of gold nanoconjugates
Size distribution of as-purchased 10nm citrate-capped AuNPs was confirmed by TEM and 
DLS (Figure 1D). The kinetics of gemcitabine loading onto the AuNPs was evaluated using 
UV-Vis spectroscopy. Citrate-capped AuNPs in borate buffer (50 μg/ml) demonstrated 
concentration- and time-dependent gemcitabine loading as suggested by a red-shift in the 
peak surface-plasmon resonance (SPR). Prolonged incubation, as well as a higher 
concentration of gemcitabine, led to aggregation of AuNPs (Figure 1A and 1B). The optimal 
concentration of gemcitabine and duration of its incubation with AuNPs was found to be 10 
μg/ml and 1-hour, respectively. Addition of C225 antibody conjugated to a linker lead to a 
further slight red-shift in the peak SPR confirming conjugation without aggregation (Figure 
1C). The surface of the ACG nanoconjugates was further passivated with 5 kDa mPEG-SH 
to prevent non-specific interactions as well as to avoid immune recognition. This increased 
the median hydrodynamic diameter from 50 nm (without mPEG) to 68 nm (with mPEG) 
(Figure 1D). The ACGP conjugate hence formed was stable after adding 150mM NaCl in 
1:1 (v:v) ratio (Figure S1A). Finally, the loading efficiency of gemcitabine in this conjugate 
was found to be 30%, as determined by HPLC, corresponding to a Gemcitabine:AuNP 
(w:w) ratio of 6%.
Stability of ACGP conjugates was also tested and confirmed in buffer solution with 
increasing protein concentration (Figure S1B). We found that gemcitabine was released in a 
pH-dependent (Figure 1E), but RF-independent manner (Figure S2A). Of the total bound, 
28.8 ± 0.4% of the gemcitabine was released at pH 6 as opposed to 8.8±0.2% at pH 7.4 after 
24 hours (p<0.05). This pH-dependent release was due to aggregation of the AuNPs as 
demonstrated by a >10 nm shift in peak SPR and broadening of the peak by UV-Vis 
spectroscopy (Figure 1D), along with dissociation of the C225 antibody from the AuNP 
surface (Figure S2B). After confirming stability, loading, and release of gemcitabine in a 
pH-responsive manner, we evaluated the heating of these conjugates in the RF field. We 
found that ACG and ACGP nanoconjugates did not heat above the background buffers 
(Figure S3).
Gold nanoconjugate uptake and cancer cell specific cytotoxicity in vitro
Despite the lack of heating from gold gemcitabine nanoconjugates in the RF field, we 
proceeded with the evaluation of these conjugates in vitro and in vivo. We reasoned that 
because of previously reported synergy between gemcitabine and hyperthermia, tissues that 
contain gemcitabine would be preferentially susceptible to the effects of RF-induced 
hyperthermia.
First, we evaluated cell surface EGFR-1 expression in a panel of six hepatocellular 
carcinoma cell lines using flow cytometry (Figure 2A). It was noted that SNU449 cells had 
the highest expression of EGFR-1 41.5± 6.7% (mean± SD). This was closely followed by 
the Hep3B cell line, 36.8±4.2%. In contrast, EGFR-1 expression was negligible in the 
HepG2 cell line. Given these findings, we evaluated ACGP uptake in the two EGFR-1-high 
cell lines and one EGFR-1-low cell line. The mechanism of uptake of anti-EGFR-coated 
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AuNPs has previously been described in detail (6, 16). The internalization is rapid with most 
of the surface bound conjugates internalized within one hour. We utilized ICP-MS and TEM 
to quantitatively and qualitatively assess the uptake of these nanoconjugates by liver cancer 
cells, respectively (Figure 2B and 2C). We note that ACGP nanoparticles are internalized 
and localized to an endolysosomal compartment after 4 hours of incubation, while cells 
incubated with isotype control AIGP nanoparticles were rarely seen to have internalized the 
nanoconjugates. The amount of Au internalized is reported in Figure 2B on a per-cell basis. 
These results demonstrate selective cell surface receptor-based internalization of conjugates 
by cancer cells after 4 hours of incubation. In contrast, uptake of ACGP or AIGP 
nanoparticles in EGFR-1-low HepG2 cells could not be detected by ICP-MS.
Next, we inquired if RF exposure of cancer cells that have selectively internalized 
gemcitabine-loaded nanoparticles enhanced targeted cell killing. For this purpose, we 
evaluated cytotoxicity using the standard MTT assay. We found that for the SNU449 cell 
line (Figure 2D), control cells that were untreated or treated with isotype nanoparticles or an 
equimolar dose of gemcitabine (12μg/ml) for 4 hours showed no cytotoxicity. However, 
ACGP nanoparticles demonstrated significant cytotoxicity compared to controls (p<0.05). 
We exposed these groups to 4.5 min of RF exposure (Kanzius RF generator, 13.56 MHz, 
600 W). This dose was found to yield ~LD25 in cells treated with RF alone. We note that the 
group that received the combination treatment with targeted nanoparticles for 4 hours, 
followed by RF exposure for 4.5 min, demonstrated the highest cytotoxicity, while the other 
RF groups were not significantly different from the RF alone group. Similar results were 
noted with experiments conducted on Hep3B cells that demonstrated EGFR-1-targeted 
gemcitabine cytotoxicity was further enhanced by RF field exposure (Figure 2E). Similar 
experiments conducted on EGFR-1-low HepG2 cells failed to show significant toxicity in 
combination therapy group compared to control groups (Figure 2F).
Chemosensitization of HCC xenografts by RF field exposure after gold nanoconjugate 
administration
A human liver cancer model was generated in a mouse subcutaneously implanted with 
EGFR-expressing Hep3B cells (Figure 3A) in the dorsal midline. The ectopic location of the 
tumor allowed easy control over thermal dosimetry by monitoring the temperature of the 
tumor in real-time using an IR thermal camera when the mouse was placed in an RF field 
(Figure 3B). Mice were randomized to one of five groups (Untreated, RF field exposure 
only, ACGP only, AIGP + RF, and ACGP + RF). As demonstrated in Figure 3C, tumors in 
the combination group with targeted nanoconjugates showed delayed growth kinetics. We 
also found that RF treatment by itself did not have an impact on tumor growth, while tumors 
in other nonspecific treatment groups demonstrated intermediate response. Tumor mass data 
is summarized in Figure 3D. One mouse in the untreated group was sacrificed because of 
tumor burden at 11 days after the start of treatment and is not included in the final tumor 
mass analysis. Figure 3D demonstrates that mice that were treated with ACGP followed by 
RF field exposure had the smallest tumors, which was significantly different from the 
control group (p=0.0003). Mice treated with ACGP alone or mice treated with AIGP 
followed by RF were smaller than the control group, however this did not reach statistical 
significance. To address the question if antibody targeting had an effect on anti-tumor 
Raoof et al. Page 7
Nanomedicine. Author manuscript; available in PMC 2015 August 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
efficacy, we compared the tumor mass of mice treated with ACGP followed by RF with 
their isotype counterparts. We found that mice in the former group had tumors that were 
significantly smaller than the mice in the latter group (p=0.015). We further asked if RF 
exposure had any added value to the mice treated with ACGP. We found that although the 
mean tumor mass of the mice treated with ACGP followed by RF (194±65) was less than 
half of the mice treated with ACGP alone (486±164 mg), it did not reach statistical 
significance (p=0.13).
Detailed histological analysis was then performed on the tumor tissues and viscera to assess 
molecular markers of response as well as to assess toxicity (Figure 4 and Figure S4). Tumor 
necrosis, as assessed by routine H&E staining, demonstrated that the RF treated groups 
generally had a 2–3 fold higher necrosis rate than other groups. However, this was not 
significant in multiple comparison tests. Tumors of mice treated with ACGP demonstrated a 
15-fold increase in apoptosis compared to untreated controls (p<0.05). Since gemcitabine is 
incorporated into the DNA and inhibits DNA synthesis, we wanted to quantify this effect in 
the tumor tissues. Twenty-four hours before sacrifice and immediately after the last RF 
exposure, mice were given BrdU 10 mg/kg IP (intra-peritoneal). The BrdU incorporation 
was measured in tissues, which provided a direct correlate of activity of gemcitabine in 
tissues. We observed that tumors treated with ACGP followed by RF had the lowest BrdU 
uptake compared to untreated controls. This was also confirmed using a marker of 
proliferation, Ki67, that demonstrated similar results.
We studied tumor accumulation and plasma levels after injecting a single intra-peritoneal 
dose of ACGP nanoparticles (at 10 mg/kg by gold concentration). We note that tumor 
accumulation increased over-time, reaching a plateau at 24–48 hours after injection (Figure 
S5). Similar dynamics were seen with accumulation in the liver and spleen. We find that 
0.52% of the injected dose accumulates in the tumor, which is comparable to 1.02% of the 
dose accumulated in liver. This demonstrates that even though nanoparticles are cleared by 
the reticuloendothelial system, significant AuNPs accumulate in the tumor tissue.
We asked if changing the route of administration could prevent the enhanced accumulation 
in the reticuloendothelial system. For that purpose, ACGP nanoparticles were injected in the 
tail vein or via an intra-peritoneal route. We noted that the Au plasma levels peak 15-min 
after intravenous injection was 6.7±1 mg/L and one-hour after intra-peritoneal injection was 
0.23±0.1 mg/L (Figure S5). This was followed by a prolonged clearance lasting more than 
24 hours. The area-under-curve for the two routes was comparable, i.e. 23.6 mg.h/L and 
15.7 mg.h/L (p=0.67) for intravenous and intraperitoneal injection, respectively. We note 
that 24 hours after injection, the levels of Au accumulated in liver tissue are not significantly 
different for either route. However, after intraperitoneal injection a significantly higher 
accumulation of ACGP nanoparticles is seen in the spleen compared to the intravenous 
administration (p=0.024). These findings suggest that intravenous administration of ACGP 
nanoparticles can partially prevent their clearance by the reticuloendothelial system in 
comparison to intraperitoneal administration.
In order to assess the safety of this modality, mice were monitored closely throughout the 
study. Histological analysis did not demonstrate any damage to native viscera in the 
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treatment groups. BrdU uptake in the spleen and intestine was similar for all groups treated, 
suggesting minimal effect on proliferation of these tissues following treatment with the 
nanoconjugates with or without RF field exposure (Figure S6).
DISCUSSION
In this series of experiments, we have demonstrated the pre-clinical activity of a carefully-
designed nanoconjugate, ACGP, in combination with brief (10 min) high intensity (600 W) 
shortwave RF field exposure against human HCC cell lines and tumors with moderate over-
expression of the target (EGFR-1). This conjugate comprised of several components each 
with an important function, as described below.
Firstly, the AuNP platform was chosen since nanotoxicology studies in small and large 
animals have failed to show any toxicity at a macroscopic as well as a molecular level (17, 
18). AuNPs also act as susceptors in a shortwave RF-field (3, 4, 6, 8), are easily 
functionalized with targeting moieties or drugs (9–12), and can be synthesized in a 
reproducible and cost-effective manner. Despite their accumulation in the liver (Kupffer 
cells), we found that these AuNPs do not harm liver parenchyma or other viscera, which is 
consistent with prior observations (6, 17). We have previously shown that AuNPs are 
predominantly eliminated by renal clearance and their elimination, therefore, should be 
independent of hepatic dysfunction(17). In regards to the choice of drug for conjugation, we 
were limited; conventional cytotoxic chemotherapies have failed to be of much benefit with 
a median survival of 7–8 months for advanced HCC which is extended for only three more 
months by use of the multiple kinase inhibitor sorafenib (2). Several factors led us to select 
gemcitabine for this purpose. A 17% response rate with gemcitabine was seen as a single 
agent in, at least, one study of patients with advanced HCC. Gemcitabine and its metabolite 
are renally cleared and it is tolerated well in these patients (19). Moreover, gemcitabine is 
heat stable and has known synergy with hyperthermia that has previously been well 
characterized in rodent models of lung cancer and rhabdomyosarcoma (20, 21). Very few 
targets have been identified in HCC that have translational relevance. We used cetuximab 
(C225) because surface EGFR-1 over-expression is associated with late stage disease and it 
is found in 66% of human HCC tumors, making it a potential target (22). It is also FDA 
approved for use in other solid tumors. We used a heterobifunctional linker for conjugation. 
From prior studies, we understood that gold nanoconjugates when prepared using this linker, 
are internalized by receptor-mediated endocytosis and within 30 min – 4 hours are found in 
late endosomes and lysosomes within the targeted cancer cells (15). Intracellular pH 
measurements around these AuNPs demonstrated that this pathway involves a transition 
from pH 7.4 in the serum to pH 5.5 or less in the lysosomes. This leads to aggregation of the 
AuNPs and dissociation of C225. In the experiments reported here, we further showed that 
gemcitabine unloading is enhanced in a pH dependent manner from this construct, thereby 
triggering only intracellular release. We were limited in quantifying the release of 
gemcitabine inside cancer cells by the lack of readily-available methods to detect 
intracellular levels of gemcitabine. Because the nanoconjugates are stable in physiologic 
conditions, we make the assumption that AuNP biodistribution and pharmacokinetics are 
representative of gemcitabine. Finally, our intention was to design particles that would not 
only reach the tumor microvasculature, but would also extravasate and permeate throughout 
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the tumor microenvironment. It has previously been shown that particles <20 nm extravasate 
and permeate too quickly through the tumor while larger particles >80 nm do not permeate 
at all (23). Untargeted AuNPs that were 40–80 nm were found to accumulate within the 
tumor stroma more readily. The conjugates were therefore designed to be between 50–70 
nm in this study.
For in vitro cell studies we administered these nanoconjugates to cancer cells for brief 
incubation periods mimicking fixed dose rate regimens of gemcitabine (e.g 10 mg/m2/min 
for 100 min resulting in ~15 uM peak plasma concentration). A much higher dose of 
gemcitabine (40 uM) for a much longer duration (4 hours) did not result in significant 
cytotoxicity compared to controls in either cell line when analyzed 24 hours later. Our 
results demonstrated that the same gemcitabine dose when delivered after conjugation to 
AuNPs results in much higher cytotoxicity against HCC cells. We further demonstrated that 
RF exposure, following internalization of gemcitabine-loaded gold nanoconjugates, 
significantly enhanced cytotoxicity. Current clinically relevant dosages are in excess of 1000 
mg/m2/wk (19). This translates to a mouse dose of 330 mg/kg/wk (FDA oncology dose 
calculator) (24). The gemcitabine dose used in the in vivo study was ~1.2 mg/kg/wk which is 
~275-fold lower than the lowest clinically relevant dose. Since the majority of the injected 
dose of the gold nanoconjugates accumulates in liver and spleen, it is possible that (in 
addition to EGFR-targeted drug delivery) these conjugates act as in vivo depots of 
gemcitabine. In this regard, we demonstrated evidence that isotype control nanoconjugates 
were partly effective in combination with RF. However, we failed to find any toxic effects 
of gemcitabine in these organs. We note a very low proliferation rate in normal liver 
parenchyma from BrdU labeling experiments. Since gemcitabine is incorporated in the S-
phase of the cell cycle, this may explain the liver sparing effect of the ACGP nanoparticles. 
The liver sparing effect could also be explained based on our previous observations that 
demonstrate Kupffer cells, but not hepatocytes to be the predominant site of accumulation of 
gold nanoparticles after systemic administration (6). These Kupffer cells are rapidly 
replaced from the systemic circulation and bone marrow without obvious consequence to 
liver parenchyma. Finally, our recent findings suggest that RF absorption and dissipation of 
heat in liver tumors is higher than normal liver parenchyma, which is predominantly due to 
the different electrical properties of the two types of tissue (25). All of these observations 
help explain the lack of toxicity to normal liver in comparison to liver tumor. Future studies 
will focus on evaluating how these findings can be translated to clinical scenarios because 
HCC frequently arises in the context of a cirrhotic liver.
The findings of this study should be interpreted with caution. The limitations of an ectopic 
tumor model are acknowledged. As more RF field compatible tools for orthotopic tumor 
thermography become available, the experiments need to be repeated in these more relevant 
orthotopic HCC models. Even though EGFR is over-expressed in 66% of human HCC, it is 
also expressed in a wide variety of normal tissues making it a relatively non-specific target. 
It is plausible that the use of EGFR-1-targeted nanoconjugates in human model could result 
in toxicity that is not observed in small animal models. We are currently evaluating more 
specific targets in HCC cells to determine the feasibility of this approach for human patients. 
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Taken together, these findings highlight a novel method that has far-reaching potential to 
deliver safe and effective combination therapies to patients with advanced HCC.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Synthesis and characterization of gold nanoconjugates
(A) Gemcitabine was loaded onto AuNPs (50 μg/ml) by passive conjugation at varying 
concentrations and UV-Vis spectra were analyzed at 1 hour after incubation at RT. (B) 
Fixed concentration (10 μg/ml) of gemcitabine was incubated with AuNPs (50 μg/ml) and 
UV-Vis spectra were analyzed at varying time points. (C) UV-Vis spectra demonstrating 
red-shift in AuNP SPR with stepwise addition of gemcitabine (10 μg/ml) for 1 hour and 
C225 (30 μg/ml) for 2 hours. A decrease in pH from 7.4–5 leads to aggregation of these 
nanoconjugates. (D) Hydrodynamic diameter distribution of stock AuNPs and final 
conjugates with and without mPEG-SH. Solid lines represents experimental observation and 
dashed lines represent curve-fit values from a Gaussian (log) distribution. (E) Release of 
gemcitabine from gold nanoconjugates is analyzed by RP-HPLC as detailed in methods at 
varying pH. For A,B,C, vertical dashed line represents a 10 nm shift from peak SPR of 
unconjugated AuNP. Peak SPRs to the right of this line along with broadening of the peak is 
evidence of aggregation.
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Figure 2. Gold nanoconjugate uptake and cytotoxicity in combination with RF-induced 
hyperthermia in vitro
(A) EGFR expression was analyzed in a panel of 6 human HCC cell lines by flow 
cytometry. (B) Gold uptake is quantified using ICP-MS in Hep3B, SNU449 or HepG2 cells 
pre-treated with ACGP particles or isotype control AIGP particles (n=3, *p<0.001 vs. 
isotype control). (C) Uptake of ACGP conjugate by Hep3B liver cancer cells after 4 hours of 
incubation. (D, E, F) Hep3B, SNU449 or HepG2 cells were incubated with or without gold 
nanoconjugates bearing gemcitabine or equimolar gemcitabine for 4 hours followed by RF 
exposure for 4.5 min. Cytotoxicity was analyzed 24 hours later using MTT assay (n=3–6, 
*p<0.05 vs. control for no RF groups and vs. RF alone for RF treated groups). AuNP-C225-
mPEG (ACP); AuNP-IgG-mPEG (AIP); AuNP-C225-gem-mPEG (ACGP); AuNP-IgG-gem-
mPEG (AIGP); Gemcitabine (Gem)
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Figure 3. Effectiveness of gold nanoconjugates in combination with RF in vivo
(A) Cell-surface EGFR expression in Hep3B xenografts (bottom) in comparison with DAB 
staining control (top). (B) A BalbC/Nu mouse is sedated and placed in an RF field on copper 
ground plate (Rx head) ~2 inches from Tx head (not shown). Animals are connected to the 
ground using copper tape to prevent electrothermal injury. Tumor temperature is monitored 
in the reference frame and thermal dose titrated. (C) Changes in tumor volume are recorded 
after the start of treatment at day 0. (n=5–7, Overall p-value from One-way ANOVA) (D) 
Tumor mass was documented 24 hours after last RF treatment or 48 hours after last 
nanoparticle treatment (Mean SD). AuNP-C225-gem-mPEG (ACGP); AuNP-IgG-gem-
mPEG (AIGP).
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Figure 4. Histological analysis of tumor tissues
Tumors harvested at the end of experiment were analyzed. Three random images were taken 
from each tumor. At least 3 tumors from each group were analyzed. Colorimetric staining 
and necrosis was quantified using CRI-Nuance multispectral microscope and inForm 
software. (p-values from one-way ANOVA, * represent level of significance at p<0.05 from 
Dunn’s multiple comparison post-test vs. control group). 1. Untreated Control, 2. AuNP-
C225-gem-mPEG (ACGP), 3. RF alone, 4. AuNP-IgG-gem-mPEG, 5. AuNP-C225-gem-
mPEG + RF. N=Necrosis
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